Please login to the form below

Not currently logged in
Email:
Password:

Cephalon CEO on leave

Cephalon CEO Frank Baldino is taking a leave of absence, with his duties being temporarily transferred to chief operating officer J Kevin Buchi

Cephalon chairman and CEO Frank Baldino is taking a medical leave of absence, with his responsibilities being temporarily transferred to chief operating officer J Kevin Buchi. The biotech company hopes that Baldino will return later this year and declined to comment on his medical condition.

Baldino, who founded the company, is 56 years old. He has been Cephalon's CEO since the company was launched 20 years ago and became chairman of the board in 1999. Under Baldino's leadership, Cephalon has launched eight products in the US and has earned a place on the Fortune 1000 annual ranking of America's largest corporations.

Before founding Cephalon, Baldino was a senior research biologist in the medical products department at EI duPont de Nemours & Company, where he was responsible for developing research strategies for identifying novel neuropharmaceutical agents. He holds a PhD in pharmacology from Temple University.

Buchi was tapped to fill the newly-created role of chief operating officer earlier this year, after a 20-year tenure with the firm that included 14 years as chief financial officer.  He joined Cephalon as controller in March 1991 and held several financial positions before being appointed chief financial officer. Earlier in his career, he held a number of financial positions with EI duPont de Nemours.

26th August 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics